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Background: Control of currently circulating re-assorted low-pathogenicity avian influenza (LPAI) H9N2 is a major
concern for both animal and human health. Thus, an improved LPAI H9N2 vaccination strategy is needed to induce
complete immunity in chickens against LPAI H9N2 virus strains. Cytokines play a crucial role in mounting both the
type and extent of an immune response generated following infection with a pathogen or after vaccination. To
improve the efficacy of inactivated LPAI H9N2 vaccine, attenuated Salmonella enterica serovar Typhimurium was
used for oral co-administration of chicken interferon-α (chIFN-α) and chicken interleukin-18 (chIL-18) as natural
immunomodulators.
Results: Oral co-administration of S. enterica serovar Typhimurium expressing chIFN-α and chIL-18, prior to
vaccination with inactivated AI H9N2 vaccine, modulated the immune response of chickens against the vaccine
antigen through enhanced humoral and Th1-biased cell-mediated immunity, compared to chickens that received
single administration of S. enterica serovar Typhimurium expressing either chIFN-α or chIL-18. To further test the
protective efficacy of this improved vaccination regimen, immunized chickens were intra-tracheally challenged with
a high dose of LPAI H9N2 virus. Combined administration of S. enterica serovar Typhimurium expressing chIFN-α
and chIL-18 showed markedly enhanced protection compared to single administration of the construct, as
determined by mortality, clinical severity, and feed and water intake. This enhancement of protective immunity was
further confirmed by reduced rectal shedding and replication of AIV H9N2 in different tissues of challenged
chickens.
Conclusions: Our results indicate the value of combined administration of chIFN-α and chIL-18 using a Salmonella
vaccine strain to generate an effective immunization strategy in chickens against LPAI H9N2.
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Avian influenza viruses (AIV) of the H9N2 subtype are
classified as low-pathogenicity viruses both by molecular
characterization and pathotyping. Among low-
pathogenicity avian influenza (LPAI) viruses, this par-
ticular subtype has attracted great concern due to its
wide host range [1], chance of genetic reassortment [2]
and possible avian-to-human transmission [3]. Thus, cir-
culation of H9N2 viruses in poultry not only causes in-
dustrial losses, but also poses a potential threat to
human health. Although the vaccine has been proved to
be highly immunogenic in laboratory trials [4] and can
prevent clinical disease and reduce viral shedding in field
conditions, it cannot prevent vaccinated poultry from
becoming infected and from shedding wild viruses in
farm settings [5]. Therefore, an improved vaccination
strategy is urgently required to control LPAI H9N2 out-
breaks in poultry farms.
Cytokines are natural mediators of innate and adaptive
immune responses which play a crucial role in control-
ling the immune system. The use of chicken cytokines is
becoming more feasible with the recent cloning of a
number of cytokine genes since the chicken’s immune
system is similar to that of mammals [6]. Recent studies
of avian cytokines identified a number of cytokines hav-
ing immunomodulatory and antiviral properties against
several viral infections. Additionally, some chicken cyto-
kines have already been proven to have potent adjuvant
activities [7]. In fact, the use of recombinant chicken
cytokines as adjuvants is attracting extensive attention
over existing oil-based or chemical adjuvants, because
they promote better protection without causing any ad-
verse site reactions or distress to chickens when admi-
nistered with a vaccine. Chicken interferon-α (chIFN-α)
belongs to type I IFNs and plays an essential role in the
host antiviral response by stimulating the T-dependent
lymphocyte system and induction of numerous IFN-
stimulated genes (ISGs) [8]. Interleukin-18 (IL-18), ori-
ginally known as potent interferon-γ (IFN-γ)-inducing
factor (IGIF), shares properties with IL-12 and both
cytokines act synergistically to promote IFN-γ produc-
tion, which is well characterized as having immunomo-
dulatory and adjuvant properties [9]. Recent studies
showed that recombinant chIL-18 has immunomodula-
tory and anti-viral properties against AIV [10]. There-
fore, both chIFN-α and chIL-18 may have great value for
use either singly or in combination in disease prevention
strategies in chickens. However, the practical mass ad-
ministration of chicken cytokines to control poultry dis-
eases is particularly limited due to the absence of a cost
effective delivery system.
To this end, we investigated the immunomodulatory
functions of chIFN-α and chIL-18 using attenuated
Salmonella enterica serovar Typhimurium as an oraldelivery vehicle. The combined oral administration of
these two cytokines using attenuated S. enterica serovar
Typhimurium modulated immune responses of chickens
against inactivated AI H9N2 vaccine through enhanced
humoral and Th1-biased cell-mediated immunity. Subse-
quently, oral co-administration of S. enterica serovar
Typhimurium expressing chIFN-α and chIL-18 con-
ferred better protection against a high-dose challenge of
homologous AI H9N2 virus. Our results indicate the
useful value of combined administration of chIFN-α and
chIL-18 using attenuated S. enterica serovar Typhimur-
ium in inactivated H9N2 LPAI vaccination.
Methods
Animals and ethics statement
SPF White Leghorn layer chickens were obtained from
OrientBio (Seongnam-Si, Korea), and reared with formu-
lated commercial feed and water provided ad libitum
throughout the experimental period. All experimental
and animal management procedures were undertaken in
accordance with the requirements of the Animal Care
and Ethics Committees of Chonbuk National University.
The animal facility of Chonbuk National University is
fully accredited by the National Association of Labora-
tory Animal Care.
Cells and viruses
LPAIV H9N2 strain, A/Chicken/Korea/01310/2001 (01310),
was provided by the National Veterinary Research and
Quarantine Service of the Republic of Korea and used for
the challenge experiments. AIV H9N2 (01310) was pro-
pagated by inoculating the allantoic cavity of 10-day-
old embryonated eggs. Allantoic fluid was harvested
96 h after inoculation and the infectious viral titer was
determined using 10-day-old embryonated eggs.
Attenuated S. enterica serovar Typhimurium expressing
chIFN-α and chIL-18
Attenuated S. enterica serovar Typhimurium expressing
chIFN-α and chIL-18 (χ8501/chIFN-α and χ8501/chIL-18)
were constructed by cloning chIFN-α and chIL-18 genes
with reverse transcriptase-PCR (RT-PCR), as described
elsewhere [11]. Briefly, after cloning chIFN-α and chIL-18
genes into the expression vector, pYA3560 and pYA3493,
by RT-PCR, attenuated S. enterica serovar Typhimurium
χ8501 (hisG Δcrp-28 ΔasdA16) was used as the host bac-
teria to deliver pYA3560 and pYA3493 harboring
chIFN-α and chIL-18 genes by electroporation. The
transformed Salmonella bacteria were selected after
plating onto LB agar plates in the absence of diamino-
pimelic acid (DAP). S. enterica serovar Typhimurium
cultures were grown at 37°C in Lennox broth, Luria-
Bertani (LB) broth, or on LB agar. DAP (Sigma;
50 μg/ml) was added to induce the growth of Asd-
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chIL-18 by S. enterica serovar Typhimurium was iden-
tified by immunoblotting following gel separation of
prepared proteins by SDS-PAGE (Data not shown).
Phosphate-buffered saline (PBS, pH 7.4) containing
0.01% gelatin (BSG) was used for the resuspension of
Salmonella bacteria that were concentrated by centri-
fugation at 7000 × g at 4°C for 5 min.
Animal experimental designs for AIV H9N2 vaccination
and challenge
A total of 40 SPF chickens (32-days-old) were divided
randomly into five groups. The first group (n= 5) was a
negative control orally administered vehicle (PBS con-
taining 0.01% gelatin) without S. enterica serovar Typhi-
murium expressing chIFN-α or chIL-18. The second
group (n = 5) was orally administered S. enterica sero-
var Typhimurium harboring pYA3560 vector
(109 cfu/chicken) as a control for the empty pYA3560
vector. The remaining three groups (n = 10 per
group), each comprising two replications (n = 5 per
replication) for two different doses, were orally admi-
nistered either S. enterica serovar Typhimurium
expressing chIFN-α (109 and 1011 cfu/chicken) or
chIL-18 (109 and 1011 cfu/chicken) or both in a com-
bination (109 and 1011 cfu/chicken). Three days after
treatment, the 35-day-old chickens from all groups
except the negative control, were vaccinated intra-
muscularly with the recommended dose of AIV
H9N2 inactivated vaccine (PoulShotW Flu H9N2;
Choong Ang Vaccine Inc., Daejeon, Korea). Chickens
receiving a primary vaccination were boosted using
the same protocol 7 days later. Blood samples were
collected 7 days after the primary vaccination and 7
and 14 days after booster vaccinations followed by
sera separation. Peripheral blood mononuclear cells
(PBMCs) were enriched from the blood of vaccinated
chickens using OptiPrepTM (13.8% iodixanol) 14 days
post-booster vaccination, according to the manufacturer’s
instructions (Axis-Shield, Oslo, Norway). To evaluate the
protective immunity of AI H9N2 vaccine in chickens co-
administered S. enterica serovar Typhimurium expressing
chIFN-α and chIL-18, SPF chickens (7-days-old) were vac-
cinated according to the same protocol and intra-
tracheally challenged with AIV H9N2 (01310) (1010.83 egg
infective dose [EID]50/chicken) 7 days after booster vaccin-
ation at 24-days–old. Following challenge, chickens were
observed daily for clinical signs and mortality throughout
the duration of the experiment. Clinical signs were scored
as follows: 0, no sign; 1, slight depression; 2, moderate de-
pression+ reduced movement+ reduced food/water intake
(anorexia); 3, moderate respiratory distress (sinusitis,
cough); 4, severe respiratory distress (sinusitis, severe
cough)+ diarrhea; 5, death. Average feed and water intakewas determined daily for 9 days after challenge. Cloacal
swab samples were collected at 0, 1, 3, 5, 7, and 9 days
post-infection (p.i.). Another experiment was performed
using the same experimental design to collect additional
samples for determination of virus amount in tissues.
Hemagglutination inhibition (HI) assay
To determine the HI titers of the sera samples collected
from vaccinated chickens, HI tests were performed with
AIV H9N2 (01310) using a standard method. The geo-
metric means of serum HI titers obtained from each
group were defined as the reciprocal logarithm in a base
of 2 of the highest serum dilution completely inhibiting
agglutination.
AIV H9N2 antigen-specific proliferation of PBMCs
AIV H9N2 antigen-specific proliferation of PBMCs was
assessed by measuring viable cell ATP bioluminescence.
Briefly, PBMCs (responder) were prepared from vacci-
nated chickens as previously described [13], and cultured
together with stimulator cells at three different ratios.
Autologous PBMCs (106 cells/ml), which were isolated
from corresponding chickens before vaccination and
kept at liquid nitrogen tank, had been pulsed with ultra-
violet (UV)-inactivated AIV H9N2 antigen (2.5×102 HA
units/ml) for 3 h followed by treatment with mitomycin
C (25 μg/ml) for 5 min, and were employed as stimula-
tor cells. Following 72 h incubation, the proliferated cells
were evaluated using a ViaLightW Cell proliferation assay
kit (Cambrex Bio Science, Rockland, ME, USA) accord-
ing to the manufacturer’s instructions. PBMC stimula-
tors that were not pulsed with UV-inactivated AIV
H9N2 antigen were used for negative control.
Real-time quantitative RT-PCR (qRT-PCR) analysis
Real-time quantitative RT-PCR (qRT-PCR) analysis was
used for determining the mRNA expression levels of
IFN-γ and IL-4 in PBMCs and the amount of AIV H9N2
in cloacal swab samples. Briefly, total RNA were extracted
from collected samples using viral and total RNA extrac-
tion kits (iNtRON), according to the manufacturer's
instructions, and then subjected to real-time qRT-PCR
using a One-Step SYBRW qRT-PCR reagent kit (Takara,
Shiga, Japan) and primers specific for the IFN-γ, IL-4, and
AIV H9 gene (Table 1). RT and real-time PCR amplifica-
tion of targeted genes were carried out under the same
reaction conditions and temperature cycles as described
previously [11]. After the reaction cycle was completed
the temperature was increased from 50°C to 95°C at a
rate of 0.2°C/15 s and fluorescence was measured every
5 s to construct a melting curve that was used to confirm
the authenticity of the amplified products. A control sam-
ple that contained no template RNA was run with each
assay, and qRT-PCR data was normalized using the
Table 1 PCR primers for amplification of chIFN-α, chIL-18, AIH9, IFN-γ, IL-4, and GAPDH
Target gene Primer sequence (5′-3′) Accession no. Reference
chIFN-αa F ATGGCTGTGCCTGCAAGCCCA DQ026259.1 -
R CTAAGTGCGCGTGTTGCCTGT
chIL-18b Fc GAATTCGCCTTTTGTAAGGATAAAACT HM854281.1 -
Rc AAGCTTTCAGTGATGGTGATGGTGATG TAGGTTGTGCCTTTC
AIH9 F CTACTGTTGGGAGGAAGAGAATGGT AF461510.1 [29]
R TGGGCGTCTTGAATAGGGTAA
IFN-γ F CAAAGCCGCACATCAAACA X99774 [30]
R TTTCACCTTCTTCACGCCATC
IL-4 F GAGAGGTTTCCTGCGTCAAG FJ907790.1 [31]
R TGGTGGAAGAAGGTACGTAGG
GAPDH F AGAACATCATCCCAGCGTCC X01578 [30]
R CGGCAGGTCAGGTCAACA
aThe primer pair specific for chIFN-α gene was designed using chIFN-α6 nucleotide sequences (Genbank accession number DQ026259.1), and the sequences of
the two primers were checked using NCBI Blast Software.
bThe primer pair specific for chIL-18 gene was designed using chIL-18 nucleotide sequences (Genbank accession number HM854281.1), and the sequences of the
two primers were checked using NCBI Blast Software.
cThe forward and reverse primers specific for chIL-18 gene contain EcoRI and HindIII restriction sites as indicated by the underline. The reverse primer also
contained 6×His-Tag sequences indicated in boldface.
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copy number of the experimental samples was deter-
mined by interpolating the threshold cycle values using
the standard curve. All data were analyzed using
CFX96TM manager software version 1.6 (Bio-Rad).
Statistical analysis
All data were expressed as the average ± standard error.
Differences between the two groups were compared
using an unpaired two-tailed Student’s t-test. Differences
between multiple groups were compared using two-way
analysis of variance (ANOVA) using SAS version 9.1
(SAS Institute Inc., Cary, NS, USA). A p-value< 0.05
was considered to indicate a statistically significant dif-
ference between the groups.
Results
Enhancement of humoral immune responses against AI
vaccine by oral co-administration of S. enterica serovar
Typhimurium expressing chIFN-a and chIL-18
In order to examine the humoral immune responses in
AIV H9N2-vaccinated chickens with or without oral co-
administration of S. enterica serovar Typhimurium
expressing chIFN-α and chIL-18, groups of chickens
(n= 5) treated with χ8501/chIFN-α or χ8501/chIL-18 or
both at two different doses (109 and 1011 cfu/chicken)
were vaccinated twice with AIV H9N2 inactivated vac-
cine. Sera samples were collected 7 days after primary
vaccination and 7 and 14 days after booster vaccination
and used for the determination of HI antibody titers. Sig-
nificantly enhanced HI antibody levels were observed at
all three time points in the sera of both χ8501/chIFN-α-and χ8501/chIL-18-administered chickens at both doses,
compared to that of χ8501 (pYA3560)-treated chickens
(Figure 1). Notably, combined oral administration of
χ8501/chIFN-α and χ8501/chIL-18 showed significantly
enhanced HI antibody titers in the sera of AI-vaccinated
chickens at both doses, compared to single administra-
tion of S. enterica serova Typhimurium expressing chIL-
18 or chIFN-α. Therefore, these results indicate that oral
co-administration of S. enterica serovar Typhimurium
expressing chIL-18 and chIFN-α produces enhanced
humoral immune responses against AI vaccine.
Co-administration of S. enterica serovar typhimurium
expressing chIFN-a and chIL-18 induces enhanced Th1-
biased immunity against AI vaccine
To evaluate cellular immune responses, PBMCs were
prepared from AIV H9N2-vaccinated chickens that
received oral co-administration of χ8501/chIFN-α and
χ8501/chIL-18, and subsequently subjected to stimula-
tion with autologous PBMCs that had been previously
pulsed with UV-inactivated AIV H9N2 antigen. PBMCs
of chickens that received χ8501/chIFN-α or χ8501/chIL-
18 (109 and 1011 cfu each per chicken) orally prior to AI
vaccination were found to have significantly enhanced
proliferation upon AIV H9N2 antigen-specific stimula-
tion, compared to PBMCs from chickens that received
χ8501/pYA3560 (vehicle) (Figure 2A). In particular, oral
co-administration of χ8501/chIFN-α and χ8501/chIL-18
produced markedly enhanced proliferation of PBMCs
upon AIV H9N2 antigen-specific stimulation than single
administration of χ8501/chIFN-α or χ8501/chIL-18. In
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Figure 1 Serum HI antibody titers of inactivated AIV-vaccinated chickens following co-administration of live attenuated S. enterica
serovar Typhimurium expressing chIFN-α and chIL-18. Groups of chickens were administered S. enterica serovar Typhimurium expressing
chIFN-α and/or chIL-18 (109 and 1011 cfu/chicken) and vaccinated with inactivated AIV H9N2 three days later. The vaccination was performed by
same protocol twice at 7-day intervals. Serum samples collected from chickens of all groups 7 days after primary vaccination and 7 and 14 days
after booster vaccination were subjected to HI testing. Data are expressed as reciprocal log2 of the geometric average and SEM of HI titers
obtained from five chickens per group. **p< 0.01; ***p< 0.001 compared to vehicle group treated with control bacteria. }}}p< 0.001 compared
to chIFN-α-treated chickens. †††p< 0.001 compared to chIL-18-treated chickens.
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lowing stimulation with AIV H9N2 antigen. Both IFN-γ
and IL-4 mRNA levels in PBMCs prepared from chickens
that received a single administration of χ8501/chIFN-α or
χ8501/chIL-18 (109 and 1011 cfu) were significantly
enhanced, compared to chickens that received S. enterica
serovar Typhimurium harboring empty pYA3560 vector.
A markedly enhanced effect on IFN-γ and IL-4 mRNA
expression in PBMCs prepared from χ8501/chIFN-α plus
χ8501/chIL-18 co-administered chickens was also
noticed (Figure 2B). More importantly, the expression of
IFN-γ mRNA was more significantly up-regulated than
IL-4 mRNA with a single administration of χ8501/chIFN-
α or χ8501/chIL-18, and co-administration of χ8501/
chIFN-α and χ8501/chIL-18 induced more enhanced
upregulation of IFN-γ mRNA than single administration
of the constructs. Taken together, our results indicate that
oral co-administration of S. enterica serovar Typhimur-
ium expressing chIFN-a and chIL-18 induces enhanced
Th1-biased immunity against an AI vaccine, compared to
single administration of S. enterica serovar Typhimurium
expressing chIL-18 or chIFN-α in chickens.
Enhanced protective immunity of AI vaccine by co-
administration of S. enterica serovar Typhimurium
expressing chIFN-a and chIL-18
To evaluate the protective immunity of AI H9N2 vac-
cine in chickens co-administered S. enterica serovarTyphimurium expressing chIFN-α and chIL-18, chick-
ens (7-days-old) co-administered S. enterica serovar
Typhimurium expressing chIFN-α and chIL-18 were
vaccinated twice at 10- and 17-days-of-age and then
intra-tracheally challenged with AIV H9N2 (01310)
(1010.83 EID50/chicken) 7 days after booster vaccination.
Following challenge, chickens were observed daily to
record mortality and clinical severity signs throughout
the duration of the experiment. Mortality occurred be-
tween 4 and 6 days p.i., and the chickens that received
S. enterica serovar Typhimurium harboring empty
pYA3560 vector without AI-vaccine had the highest
mortality (50%). Vaccination with inactivated AI vaccine
reduced the mortality to 25% and oral administration
of χ8501/chIFN-α or χ8501/chIL-18 (109 cfu) prior to
AI vaccination reduced it further to 12.5%. However,
single administration of either χ8501/chIFN-α or χ8501/
chIL-18 at a higher dose (1011 cfu) or combined adminis-
tration at either dose (109 and 1011 cfu) effectively pro-
tected all vaccinated chickens from mortality caused by
AIV H9N2 challenge (Figure 3A). Also, when the severity
of clinical signs caused by AIV H9N2 challenge infection
was scored, clinical signs appeared 2 days p.i., and the se-
verity of clinical signs peaked at 4–7 days p.i. (Figure 3B).
Chickens that received single or combined administra-
tion of χ8501/chIFN-α and χ8501/chIL-18 (109 and
1011 cfu) showed significant alleviation of clinical severity




















































































































Figure 2 Enhanced Th1-biased immunity in chickens that received the co-administration of S. enterica serovar Typhimurium
expressing chIFN-α and chIL-18. (A) AIV H9N2 antigen-specific proliferation of PBMCs. Groups of chickens were administered S. enterica serovar
Typhimurium expressing chIFN-α and chIL-18 (109 and 1011 cfu/chicken) and vaccinated with inactivated AIV H9N2 three days later. The
vaccination was performed by same protocol twice at 7-day intervals. PBMCs (responders) were prepared from chickens 14 days after booster
vaccination, and subsequently stimulated with naïve PBMCs (stimulators) that had been pulsed with inactivated AIV H9N2 antigen. AIV H9N2
antigen-specific proliferation of PBMCs was assessed by measuring viable cell ATP bioluminescence following incubation for 72 h. (B) The
expression of IFN-γ and IL-4 mRNA by PBMCs following stimulation with AIV H9N2 antigen. Total RNA was extracted from PBMCs stimulated with
AIV H9N2 antigen for 72 h, and subjected to real-time qRT-PCR to determine the expression of IFN-γ and IL-4. Data show the average and SEM of
IFN-γ and IL-4 mRNA expression normalized to GAPDH (n= 5). ***p< 0.001 compared to vehicle group treated with control bacteria. p< 0.001
compared to chIFN-α-treated chickens. †††p< 0.001 compared to chIL-18-treated chickens.
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Typhimurium harboring empty pYA3560 vector (ve-
hicle). Furthermore, average feed and water intake
improved in chickens that received the AI vaccine, com-
pared to chickens that received only empty vector
(χ8501/pYA3560) (Figure 3C and D). In particular, aver-
age feed and water intake improved more when the
chickens received χ8501/chIFN-α and χ8501/chIL-18 ei-
ther singly or in combination (109 and 1011 cfu) before
vaccination with better result from the later. Overall,
these results indicate that oral co-administration of
S. enterica serovar Typhimurium expressing chIFN-a and
chIL-18 prior to AI vaccination could markedly reducemortality and alleviate clinical signs induced by infection
with AIV H9N2. Furthermore, when we examined histo-
pathological changes in lung and tracheal tissues of
chickens 5 days after AIV H9N2 challenge infection,
those that received χ8501/chIFN-α and χ8501/chIL-18
either singly or in combination (109 and 1011 cfu) had ap-
parently normal lungs and trachea, compared to chickens
that received only empty vector without AI vaccine (data
not shown). These results indicate that oral co-
administration of S. enterica serovar Typhimurium
expressing chIFN-a and chIL-18 along with AI vaccine
could provide better protection against damage of lung
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Figure 3 (See legend on next page.)
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Figure 3 Enhanced protective immunity of inactivated AI H9N2 vaccine by co-administration of S. enterica serovar Typhimurium
expressing chIFN-a and chIL-18. (A) Mortality of AIV H9N2-challenged chickens. Groups of chickens were administered S. enterica serovar
Typhimurium expressing chIFN-α and chIL-18 (109 and 1011 cfu/chicken) and vaccinated with inactivated AIV H9N2 three days later. Vaccination
was performed twice at 7-day intervals. Seven days after booster vaccination, chickens were intra-tracheally infected with AIV H9N2 (1010.83 EID50/
bird). Graphs show the proportion of surviving chickens on days p.i. (B) Clinical severity of AIV H9N2-challenged chickens. Chickens immunized
with inactivated AIV H9N2 vaccine were challenged with AIV H9N2 virus and clinical severity scored daily. (C and D) Feed and water intake of AIV
H9N2-challenged chickens recorded daily after AIV H9N2 challenge of inactivated AIV H9N2-vaccinated chickens. Data show the average feed (C)
and water (D) intake obtained from eight chickens per group.
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vaccinated chickens
To evaluate the effect of oral co-administration of
χ8501/chIFN-α and χ8501/chIL-18 on virus shedding
from AIV H9N2-infected chickens that received cyto-
kine treatment and AI vaccine, the amount of virus in
cloacal swabs was determined by real-time qRT-PCR at
0, 1, 3, 5, 7 and 9 days post-challenge. Virus shedding
was detected from 3 day after AIV H9N2 infection and
peaked at 5 days p.i. (Figure 4A). However, the chickens
that received χ8501/chIFN-α or χ8501/chIL-18 or both
(109 and 1011 cfu) before AI-vaccine had significantly
lower peak levels of virus shedding at 3, 5, 7 and 9 days
p.i., with a better effect from combined treatment, com-
pared to the chickens that received only the vehicle
(χ8501/pYA3560) or the vehicle plus AI vaccine. Add-
itionally, the amount of virus in different tissues (tra-
chea, lung, brain, cecal tonsil, spleen, and kidney) of
AIV H9N2-infected chickens was determined at 4 and
7 days p.i. As expected, the amount of AIV H9N2 in dif-
ferent tissues of chickens that received χ8501/chIFN-α
or χ8501/chIL-18 or both (109 and 1011 cfu) prior to AI
vaccination was significantly lower at both 4 (Figure 4B)
and 7 days p.i. (Figure 4C), compared to chickens that
received vehicle (χ8501/pYA3560). It was also noted that
administration of only AI vaccine could significantly re-
duce the virus amounts in different tissues, compared to
vehicle (χ8501/pYA3560) but significant differences
existed when vehicle and AI vaccine were compared to
cytokines (chIFN-α or chIL-18 or both) plus AI-vaccine,
which indicates that cytokine treatment before vaccin-
ation provided better protection than vaccination alone.
Taken altogether, these results indicate that oral co-
administration of S. enterica serovar Typhimurium
expressing chIFN-a and chIL-18 along with AI vaccine
could alleviate clinical signs induced by AIV H9N2 in-
fection through reduction of virus replication in tissues.
Discussion
In the present study, we demonstrate that oral co-
administration of chIFN-α and chIL-18 using attenuated
S. enterica serovar Typhimurium modulated the immune
responses of chickens against inactivated LPAI H9N2
vaccine antigen by enhancing both humoral and Th1-biased cell mediated immunity, thereby conferring better
protection against homologous virus challenge. Thus, we
propose that modulation of the immune response eli-
cited by commercially available, inactivated LPAI H9N2
vaccine through combined use of chIFN-α and chIL-18
may provide a novel approach to induce complete im-
munity in chickens against H9N2 LPAI virus strains.
The enhanced effect of cytokine combinations has
been shown empirically, based on their biological
mechanisms. IFN-α and β (type I IFNs) rapidly induced
by viral infection and/or a series of events have well-
defined strong antiviral activity along with immunoregu-
latory functions. The binding of type I IFNs to type I
IFN receptor complexes results in the rapid phosphoryl-
ation and activation of receptor-associated JAKs, Tyk2,
and Jak1, and subsequent transcription factor STAT1/2,
which induces the expression of OAS, RNase L, Mx1,
and PKR genes that confer the antiviral state in cells [8].
Alternatively, IFN-γ, the only type II IFN, is a multifunc-
tional cytokine produced primarily by T lymphocytes
(Th1) and natural killer (NK) cells and IL-18 induces its
production. It has been confirmed that after infection of
macrophages with influenza virus, cells produce IL-18,
which acts synergistically with IFN-α and enhances IFN-γ
synthesis [14]. IFN-γ plays a vital role in macrophage acti-
vation and modulation of the immune system, in addition
to its antiviral activity [15]. Similar to mammalian IFNs,
chicken type I and type II IFNs act synergistically [16],
both in terms of antiviral activity and in their ability to ac-
tivate macrophages. Therefore, it is possible that chIFN-α
and chIL-18 might have enhanced immunomodulatory
functions when combined; however, a practical assessment
of their joint function in immune modulation has not yet
been addressed. It is conceivable that type II IFN-γ pro-
duced by IL-18 exposure might induce enhanced allevi-
ation of the clinical signs of AIV H9N2 infection and
modulate immunity, along with type I IFNs. Furthermore,
our results are supported by the finding that chic-
ken IL-18 cDNA linked with the recombinant encod-
ing sequences of H5-H7 AIV in a fowl pox-based
DNA vaccine (rFPV-H5-H7-IL18) successfully induced
complete protection (100%) in SPF chickens after
challenge with H5 AIV, and lymphocyte proliferation













































































































































































































































































































Figure 4 Reduction of virus shedding and replication in AIV H9N2-challenged chickens co-administered S. enterica serovar
Typhimurium expressing chIFN-α and chIL-18 followed by AIV H9N2 vaccination. (A) Virus shedding of vaccinated chickens after AIV H9N2
challenge. Groups of chickens co-administered S. enterica serovar Typhimurium expressing chIFN-α and chIL-18 (109 and 1011 cfu/chicken)
followed by inactivated AIV H9N2 vaccination were intratracheally challenged with AIV H9N2 (1010.83 EID50/bird). Amounts of AIV H9N2 in cloacal
swab samples taken at the indicated dates post-challenge were determined by real-time qRT-PCR using primers specific for hemagglutinin
protein of AIV H9N2. Data represent the average and SEM of five chickens per group. (B and C) The amount of virus in tissues of AIV H9N2-
challenged chickens. Groups of chickens that were co-administered S. enterica serovar Typhimurium expressing chIFN-α and chIL-18 (109 and
1011 cfu/chicken) followed by inactivated AIV H9N2 vaccination were euthanized 4 (B) and 7 days (C) after AIV H9N2 challenge. Real-time qRT-PCR
using total RNA extracted from tissues (trachea, lung, brain, cecal tonsil, spleen, and kidney) was conducted to determine AIV H9N2 amounts.
Data show the average and SEM of AIV H9 fold expression obtained from four chickens per group, after normalized to GAPDH. **p< 0.01;
***p< 0.001 compared to vehicle group that was treated with control bacteria. }p< 0.05 compared to chIFN-α-treated chickens. †p< 0.05
compared to chIL-18-treated chickens.
Rahman et al. BMC Veterinary Research 2012, 8:105 Page 9 of 11
http://www.biomedcentral.com/1746-6148/8/105
Rahman et al. BMC Veterinary Research 2012, 8:105 Page 10 of 11
http://www.biomedcentral.com/1746-6148/8/105higher than that induced by rFPV-H5-H7 alone [17].
Therefore, the present data for the first time provide
valuable insight into the use of combined administra-
tion of type I IFN and IL-18 in controlling viral infec-
tion in the poultry industry.
The primary target cells for AIV infection and replica-
tion are ciliated epithelial cells. However, AIV can also
infect macrophages and dendritic cells [18]. In avian spe-
cies, intestinal epithelia are also targets of infection and,
in the later stage of infection, mononuclear cells become
involved [19]. Influenza A virus causes NS1-mediated
suppression of selected genes involved in IFN and IFN-
inducible gene expression [20], and induction of a weak
chemokine expression in human lung epithelial cells
[20], which enables the virus to replicate before the host
inflammatory and antiviral responses are activated. Thus,
complete protection of chickens from AIV H9N2
requires early stimulation of the immune system by
immunomodulatory cytokines like chIFN-α and chIL-18.
Therefore, it is possible that oral co-administration of
attenuated Salmonella bacteria expressing chIFN-α and
chIL-18 prior to vaccination with inactivated H9N2
LPAI could effectively modulate host innate and adaptive
immune responses, thereby providing complete protec-
tion against AIV H9N2 challenge.
There are a few obstacles to the practical use of mass
administration of cytokine proteins in livestock and
poultry, such as cost, labor, and time, as well as protein
stability. Establishment of a suitable delivery vector is of
prime importance to enable the use of cytokines in dis-
ease prevention in this setting. Our previous report [11]
and present study demonstrated the value of attenuated
Salmonella vaccine in the oral delivery of immunomodu-
latory cytokines. Genetically modified Lactococcus lactis
secreting bioactive cytokine has been found to be a use-
ful tool for live mucosal delivery [21, 22]. L. lactis is a
safe vector for delivery of foreign genes via foodstuffs to
the digestive tract without colonization [21, 22], yet ef-
fectively induces local immune responses [23]. In con-
trast, live recombinant Salmonella vaccine can colonize
gut-associated lymphoid tissue and visceral non-
lymphoid and lymphoid tissues following oral adminis-
tration, and subsequently stimulate local and systemic
immune responses [24]. Therefore, attenuated live
Salmonella vaccines may be a useful means to deliver
bioactive cytokines to systemic as well as mucosal
lymphoid tissues. Furthermore, attenuated S. enterica
serovar Typhimuirum is a well-characterized vaccine
strain available to livestock industry for the prevention
of salmonellosis. A registered Salmonella vaccine has the
potential for heterologous antigen delivery in livestock
vaccination [25]. Also, since the Salmonella bacteria
used in this study were devoid of the asd gene that is es-
sential for a balanced-lethal host-vector system, theymay have been sufficiently attenuated in their capacity
to cause acute diseases in chickens and are genetically
stable [26]. Accordingly, attenuated Salmonella vaccine
expressing chIFN-α and chIL-18 produced no apparent
side effect during the examination periods. However, to
accomplish the control of infectious diseases in chickens
effectively with a Salmonella delivery system, successful
and prolonged colonization of S. enterica serovar Typhi-
murium expressing chIFN-α and chIL-18 may be neces-
sary. According to previous findings, S. enterica serovar
Typhimurium can persist in adult chickens for at least
three weeks and in younger chickens up to seven weeks
[27, 28], but may be cleared ultimately. Therefore, it is
believed that the Salmonella bacteria used for cytokine
delivery can persist in chickens for 3-7 weeks, depending
on age of chickens, and can provide continuous long
term protection against virus infection.
Conclusions
We have demonstrated that enhanced modulation of im-
mune responses elicited by commercially available, inac-
tivated H9N2 LPAI vaccine through combined oral
administration of S. enterica serovar Typhimurium
expressing chIFN-α and chIL-18 can protect immunized
chickens from high-dose challenge of homologous virus.
The results suggest that naturally occurring immunomo-
dulatory cytokines like chIFN-α and chIL-18 can be
combined with commercially available inactivated vac-
cines to generate an effective immunization strategy in
chickens. It will be interesting to assess the protective ef-
ficacy of this immunization strategy against challenge
with currently circulating heterologous virus strains in
future studies.
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